Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Good news, right? Well, kinda. Under CEO David Joyner, a 30-year company veteran who took over in October, the company has ...

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

The insurance business is shaky but care delivery subsidiaries such as Optum, Evernorth Health Services, CenterWell and ...

Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.

The unorthodox firm is profiting from the AI and Trumpian revolutions ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Investors have concluded that America Inc is reliving the covid shock on fast-forward. Within a month of Mr Trump’s surprise ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.